Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.

de Gooijer MC, Buil LCM, Çitirikkaya CH, Hermans J, Beijnen JH, van Tellingen O.

Mol Pharm. 2018 Nov 5;15(11):5236-5243. doi: 10.1021/acs.molpharmaceut.8b00742. Epub 2018 Oct 5.

PMID:
30252484
2.

An Experimenter's Guide to Glioblastoma Invasion Pathways.

de Gooijer MC, Guillén Navarro M, Bernards R, Wurdinger T, van Tellingen O.

Trends Mol Med. 2018 Sep;24(9):763-780. doi: 10.1016/j.molmed.2018.07.003. Epub 2018 Jul 30. Review.

PMID:
30072121
3.

MELK Inhibition in Diffuse Intrinsic Pontine Glioma.

Meel MH, de Gooijer MC, Guillén Navarro M, Waranecki P, Breur M, Buil LCM, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso A, Bugiani M, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-0924. [Epub ahead of print]

PMID:
30061363
4.

Buparlisib is a brain penetrable pan-PI3K inhibitor.

de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O.

Sci Rep. 2018 Jul 17;8(1):10784. doi: 10.1038/s41598-018-29062-w.

5.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O.

Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28.

6.

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.

Maia ARR, Linder S, Song JY, Vaarting C, Boon U, Pritchard CEJ, Velds A, Huijbers IJ, van Tellingen O, Jonkers J, Medema RH.

Br J Cancer. 2018 Jun;118(12):1586-1595. doi: 10.1038/s41416-018-0081-2. Epub 2018 May 8.

PMID:
29736010
7.

Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8.

Berenguer J, Lagerweij T, Zhao XW, Dusoswa S, van der Stoop P, Westerman B, de Gooijer MC, Zoetemelk M, Zomer A, Crommentuijn MHW, Wedekind LE, López-López À, Giovanazzi A, Bruch-Oms M, van der Meulen-Muileman IH, Reijmers RM, van Kuppevelt TH, García-Vallejo JJ, van Kooyk Y, Tannous BA, Wesseling P, Koppers-Lalic D, Vandertop WP, Noske DP, van Beusechem VW, van Rheenen J, Pegtel DM, van Tellingen O, Wurdinger T.

J Extracell Vesicles. 2018 Mar 13;7(1):1446660. doi: 10.1080/20013078.2018.1446660. eCollection 2018.

8.

Serum Testosterone by Liquid Chromatography Tandem Mass Spectrometry for Routine Clinical Diagnostics.

van Winden LJ, van Tellingen O, van Rossum HH.

Methods Mol Biol. 2018;1730:93-102. doi: 10.1007/978-1-4939-7592-1_7.

PMID:
29363068
9.

BCRP expression in schwannoma, plexiform neurofibroma and MPNST.

de Vries M, van Tellingen O, van der Mey AGL, Bunt AMG, Bruijn IB, Hogendoorn PCW.

Oncotarget. 2017 Sep 16;8(51):88751-88759. doi: 10.18632/oncotarget.21075. eCollection 2017 Oct 24.

10.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2018 Jun;59(6):973-979. doi: 10.2967/jnumed.117.195800. Epub 2017 Nov 24.

PMID:
29175983
11.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O.

Invest New Drugs. 2018 Jun;36(3):380-387. doi: 10.1007/s10637-017-0539-8. Epub 2017 Nov 17.

PMID:
29147815
12.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O.

Int J Cancer. 2018 Jan 15;142(2):381-391. doi: 10.1002/ijc.31052. Epub 2017 Oct 4.

PMID:
28921565
13.

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Pencheva N, de Gooijer MC, Vis DJ, Wessels LFA, Würdinger T, van Tellingen O, Bernards R.

Cell Rep. 2017 Jul 5;20(1):48-60. doi: 10.1016/j.celrep.2017.06.036.

14.

The G2 checkpoint-a node-based molecular switch.

de Gooijer MC, van den Top A, Bockaj I, Beijnen JH, Würdinger T, van Tellingen O.

FEBS Open Bio. 2017 Mar 4;7(4):439-455. doi: 10.1002/2211-5463.12206. eCollection 2017 Apr.

15.

A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients.

Korse CM, Buning-Kager JCGM, Linders TC, Heijboer AC, van den Broek D, Tesselaar MET, van Tellingen O, van Rossum HH.

Clin Chim Acta. 2017 Jun;469:130-135. doi: 10.1016/j.cca.2017.04.001. Epub 2017 Apr 4.

PMID:
28385629
16.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N.

Drug Deliv Transl Res. 2017 Feb;7(1):125-131. doi: 10.1007/s13346-016-0346-3.

PMID:
27864786
17.

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.

Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, van Tellingen O.

Clin Cancer Res. 2017 Mar 1;23(5):1286-1298. doi: 10.1158/1078-0432.CCR-16-1276. Epub 2016 Aug 23.

18.

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

Loayza-Puch F, Rooijers K, Buil LC, Zijlstra J, Oude Vrielink JF, Lopes R, Ugalde AP, van Breugel P, Hofland I, Wesseling J, van Tellingen O, Bex A, Agami R.

Nature. 2016 Feb 25;530(7591):490-4. doi: 10.1038/nature16982. Epub 2016 Feb 15.

PMID:
26878238
19.

Neurobiological changes by cytotoxic agents in mice.

Seigers R, Loos M, Van Tellingen O, Boogerd W, Smit AB, Schagen SB.

Behav Brain Res. 2016 Feb 15;299:19-26. doi: 10.1016/j.bbr.2015.10.057. Epub 2015 Nov 18.

PMID:
26602283
20.

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D.

J Neurol. 2016 Mar;263(3):428-40. doi: 10.1007/s00415-015-7919-9. Epub 2015 Oct 17. Review.

PMID:
26477024
21.

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

Durmus S, Lozano-Mena G, van Esch A, Wagenaar E, van Tellingen O, Schinkel AH.

Mol Pharm. 2015 Dec 7;12(12):4259-69. doi: 10.1021/acs.molpharmaceut.5b00453. Epub 2015 Oct 29.

PMID:
26474710
22.

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LC, Beijnen JH, van Tellingen O.

Invest New Drugs. 2015 Oct;33(5):1012-9. doi: 10.1007/s10637-015-0266-y. Epub 2015 Jul 1.

PMID:
26123925
23.

Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.

Cordeiro Pedrosa LR, van Tellingen O, Soullié T, Seynhaeve AL, Eggermont AM, Ten Hagen TL, Verheij M, Koning GA.

Eur J Pharm Biopharm. 2015 Aug;94:207-19. doi: 10.1016/j.ejpb.2015.05.003. Epub 2015 May 14.

PMID:
25982691
24.

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

Zhang P, de Gooijer MC, Buil LC, Beijnen JH, Li G, van Tellingen O.

Int J Cancer. 2015 Oct 15;137(8):2007-18. doi: 10.1002/ijc.29566. Epub 2015 Apr 24.

25.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
26.

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

de Vries NA, Hulsman D, Akhtar W, de Jong J, Miles DC, Blom M, van Tellingen O, Jonkers J, van Lohuizen M.

Cell Rep. 2015 Jan 14. pii: S2211-1247(14)01057-2. doi: 10.1016/j.celrep.2014.12.028. [Epub ahead of print]

27.

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.

Invest New Drugs. 2014 Dec;32(6):1083-95. doi: 10.1007/s10637-014-0143-0. Epub 2014 Jul 31.

PMID:
25078948
28.

Cognitive impact of cytotoxic agents in mice.

Seigers R, Loos M, Van Tellingen O, Boogerd W, Smit AB, Schagen SB.

Psychopharmacology (Berl). 2015 Jan;232(1):17-37. doi: 10.1007/s00213-014-3636-9. Epub 2014 Jun 4.

PMID:
24894481
29.

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Würdinger T, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2014 May 15;20(10):2703-13. doi: 10.1158/1078-0432.CCR-14-0084. Epub 2014 Mar 19.

30.

In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.

Durmus S, Naik J, Buil L, Wagenaar E, van Tellingen O, Schinkel AH.

Int J Cancer. 2014 Oct 1;135(7):1700-10. doi: 10.1002/ijc.28797. Epub 2014 Mar 4.

31.

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ, Windhorst B, van Dongen GA, de Vries HE, Maussang D, van Tellingen O.

PLoS One. 2014 Jan 8;9(1):e82331. doi: 10.1371/journal.pone.0082331. eCollection 2014.

32.

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, Schinkel AH.

Mol Cancer Ther. 2014 Feb;13(2):492-503. doi: 10.1158/1535-7163.MCT-13-0541. Epub 2013 Nov 5.

33.

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.

Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E.

Cancer Res. 2013 Nov 15;73(22):6745-56. doi: 10.1158/0008-5472.CAN-13-0837. Epub 2013 Oct 1.

34.

Chemotherapy-related cognitive dysfunction: current animal studies and future directions.

Seigers R, Schagen SB, Van Tellingen O, Dietrich J.

Brain Imaging Behav. 2013 Dec;7(4):453-9. doi: 10.1007/s11682-013-9250-3. Review.

PMID:
23949877
35.

Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.

Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, Geerts D, De Witt Hamer PC, Hagemann C, Vandertop WP, Van Tellingen O, Noske DP, Gray NS, Würdinger T.

J Natl Cancer Inst. 2013 Sep 4;105(17):1322-31. doi: 10.1093/jnci/djt168. Epub 2013 Aug 12.

36.

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.

Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J.

Nat Commun. 2013;4:1908. doi: 10.1038/ncomms2921.

37.

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O.

CNS Oncol. 2013 May;2(3):271-88. doi: 10.2217/cns.13.15. Review.

38.

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2013 Apr 15;19(8):2084-95. doi: 10.1158/1078-0432.CCR-12-3105. Epub 2013 Mar 5.

39.

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O.

Int J Cancer. 2013 Sep 1;133(5):1222-33. doi: 10.1002/ijc.28126. Epub 2013 Apr 1.

40.

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O.

Eur J Cancer. 2013 May;49(8):2059-64. doi: 10.1016/j.ejca.2012.12.028. Epub 2013 Feb 17.

PMID:
23422148
41.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH.

Invest New Drugs. 2013 Oct;31(5):1125-35. doi: 10.1007/s10637-013-9923-1. Epub 2013 Jan 13. Erratum in: Invest New Drugs. 2013 Jun;31(3):800.

PMID:
23315030
42.

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

Zander SA, Beijnen JH, van Tellingen O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jan 15;913-914:129-36. doi: 10.1016/j.jchromb.2012.11.003. Epub 2012 Dec 6.

PMID:
23291288
43.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S.

PLoS One. 2012;7(9):e45248. doi: 10.1371/journal.pone.0045248. Epub 2012 Sep 17.

44.

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15;901:9-17. doi: 10.1016/j.jchromb.2012.05.033. Epub 2012 Jun 8.

PMID:
22727754
45.

Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.

Borovski T, Beke P, van Tellingen O, Rodermond HM, Verhoeff JJ, Lascano V, Daalhuisen JB, Medema JP, Sprick MR.

Oncogene. 2013 Mar 21;32(12):1539-48. doi: 10.1038/onc.2012.172. Epub 2012 May 21.

PMID:
22614016
46.

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

Lin F, Sherris D, Beijnen JH, Van Tellingen O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Dec 15;879(32):3823-31. doi: 10.1016/j.jchromb.2011.10.028. Epub 2011 Oct 29.

PMID:
22100549
47.

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.

Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH.

Drug Metab Dispos. 2011 Aug;39(8):1338-44. doi: 10.1124/dmd.111.038794. Epub 2011 May 12.

48.

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD.

J Clin Pharmacol. 2012 Mar;52(3):370-80. doi: 10.1177/0091270010397051. Epub 2011 Apr 19.

PMID:
21505085
49.

High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.

van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2011 Jan 15;17(2):294-301. doi: 10.1158/1078-0432.CCR-10-1980. Epub 2010 Nov 19.

50.

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O.

Invest New Drugs. 2012 Apr;30(2):443-9. doi: 10.1007/s10637-010-9569-1. Epub 2010 Oct 21.

PMID:
20963470

Supplemental Content

Loading ...
Support Center